Business
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218
About this update from Hcw Biologics Inc.
[{"type":"text","content":"Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead product candidates of HCW Biologics Inc. MIRAMAR, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that data will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota. A poster will be presented by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota who serves as a Principal Investigator of this trial. HCW Biologics has also initiated a Company-sponsored Phase 1b/2 clinical trial in patients with chemo-refractory/chemo-resistant pancreatic cancer and dosed two patients in October 2022. The Company selected chemo-refractory/chemo-resistant solid tumors for its first clinical indications because solid tumor cancers are characterized by a dense fibrotic stroma or desmoplasia that allows a tumor to shield itself from standard-of-care treatment, such as chemotherapy and immune-checkpoint inhibitors. The immunosuppressive growth factor, TGF-β, plays a major role in formation of desmoplasia and promoting tumor growth and metastasis. HCW9218 is an injectable, bifunctional fusion protein complex designed to simultaneously stimulate effector T cell and natural killer cell responses and inhibit the activity of TGF-β and its immunosuppressive effect. The Company believes these combined capabilities may define a new category of cancer treatment accomplished by modifying factors related to drug resistance and disease recurrence, especially for the most difficult to treat cancers that are chemo-refractory/chemo-resistant. Details of the presentation are as follows: Title: A phase I study of HCW9218, a bifunctional TGF-β antagonist/IL-15 ...